Nothing Special   »   [go: up one dir, main page]

AR048254A1 - NEW BETA-CETOAMIDE COMPOUNDS WITH ANCHANGISTIC EFFECT OF MCH AND MEDICINES CONTAINING THESE COMPOUNDS - Google Patents

NEW BETA-CETOAMIDE COMPOUNDS WITH ANCHANGISTIC EFFECT OF MCH AND MEDICINES CONTAINING THESE COMPOUNDS

Info

Publication number
AR048254A1
AR048254A1 ARP050100829A ARP050100829A AR048254A1 AR 048254 A1 AR048254 A1 AR 048254A1 AR P050100829 A ARP050100829 A AR P050100829A AR P050100829 A ARP050100829 A AR P050100829A AR 048254 A1 AR048254 A1 AR 048254A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
amino
cycloalkyl
phenyl
Prior art date
Application number
ARP050100829A
Other languages
Spanish (es)
Inventor
Gerald Juergen Roth
Philipp Lustenberger
Dirk Stenkamp
Stephan Georg Mueller
Thorsten Lehmann-Lintz
Marcus Schindler
Leo Thomas
Ralf Lotz
Marco Santagostino
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR048254A1 publication Critical patent/AR048254A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
    • C07C211/45—Monoamines
    • C07C211/46—Aniline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/80—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere a compuestos beta-cetoamida de formula general (1) en la cual: R1, R2 independientemente entre sí significan H, un grupo alquilo C1-8 o cicloalquilo C3-7 mono o polisustituido eventualmente con el radical R11, donde un grupo - CH2- puede estar sustituido en posicion 3 o 4 de un grupo cicloalquilo de 5, 6 o 7 miembros con -O-, -S- o -NR13, o un radical fenilo o piridinilo eventualmente mono o polisustituido con el radical R20 y/o con nitro, o R1 y R2 forman un puente alquileno C2-8, en el cual uno o dos grupos -CH2- independientemente entre sí pueden estar sustituidos con -CH=N- o -CH=CH- y/o uno o dos grupos -CH2- independientemente entre sí pueden estar sustituidos con -O, -S, -SO, -(SO2), -CO, -C(=CH2)- o - NR13- de modo tal, que los heteroátomos no estén unidos directamente entre sí, y que un grupo -CO- no esté unido directamente con el grupo R1R2N, donde el puente alquileno anteriormente definido uno o varios átomos H pueden estar sustituidos con R14, y donde el puente alquileno previamente definido puede estar sustituido con uno o dos grupos Cy carbo o heterocíclicos iguales o diferentes de modo tal, que la union entre el puente alquileno y el grupo Cy se realiza a través de una union simple o doble, a través de un átomo de C conjunto mediante la formacion de un sistema de anillo espirocíclico, a través e dos átomos de C y/o N conjuntos, adyacentes mediante la formacion de un sistema de anillo bicíclico condensado o a través de tres o más átomos C y/o N mediante la formacion de un sistema de anillo puenteado, R3 H, alquilo C1-6, cicloalquilo C3-7, cicloalquilo C3-7-alquilo C1-4- o fenilalquilo C1-3; X un puente alquileno C1-8, en el cual un grupo -CH2, que no está unido directamente con el grupo R1R2N, puede sustituirse con -CH=CH- o -C:::C- y/o uno o dos grupos -CH2- no adyacentes, que no están unidos directamente con el grupo R1R2N, pueden estar sustituidos independientemente entre sí con -O, -S, -(SO), -(SO2), - CO- o -NR4- de modo tal que en cada caso dos átomos O, S o N o un átomo O con un átomo S no están unidos directamente entre sí, donde el puente X puede estar unido con R1 incluyendo el átomo de N unido con R1 y X formando un grupo heterocíclico, donde el puente X adicionalmente también puede estar unido con R2 incluyendo el átomo N unido con R2 y X formando un grupo heterocíclico, y donde dos átomos C o un átomo C y un átomo N del puente alquileno pueden unirse entre sí por un puente alquileno C1-4 adicional y donde un átomo C no unido directamente con un heteroátomo puede estar sustituido con R10 y/o uno o dos átomos C sustituidos en cada caso con uno o dos sustituyentes iguales o diferentes seleccionados de alquilo C1-6, alquenilo 2-6, alquinilo C2-6, -cicloalquilo C3-7, cicloalquilo C3-7-alquilo C1-3, -cicloalquenilo C4-7 y cicloalquenilo C4-7-alquilo C1-3, donde dos sustituyentes alquilo y/o alquenilo pueden estar unidos entre sí formando un sistema de anillos carbocíclico, y Z una union simple o -CR7aR7b-CR7cR7d, Y uno de los significados indicados para Cy, donde R1 puede estar unido con Y incluyendo el grupo X y el átomo N unido con R1 y X formando un grupo heterocíclico condensado en Y, y/o donde X puede estar unido con Y formando un grupo carbo o heterocíclico condensado en Y, y A uno de los significados indicados para Cy, B uno de los significados indicados para Cy, b el valor 0 o 1; Cy un grupo carbo o heterocíclico seleccionado de uno de los siguientes significados: un grupo carbocíclico saturado de 3 a 7 miembros, un grupo carbocíclico no saturado de 4 a 7 miembros, un grupo fenilo, un grupo heterocíclico saturado de 4 a 7 miembros o no saturado de 5 miembros con un átomo N, O o S como heteroátomo, un grupo heterocíclico saturado o no saturado de 5 a 7 miembros con dos o varios átomos N o con uno o dos átomos N y un átomo O o S como heteroátomos, un grupo aromático heterocíclico de 5 o 6 miembros con uno o varios heteroátomos iguales o diferentes seleccionados de N, O y/o S, donde los grupos de 4, 5, 6- o 7 miembros pueden estar unidos en forma a través de dos átomos C conjuntos adyacentes condensados con un anillo fenilo o piridino, y donde en los grupos de 5, 6- o 7 miembros antes mencionados, uno o dos grupos no adyacentes -CH2- independientemente entre sí pueden estar sustituidos con un grupo -CO, -C(=CH2), -(SO)- o -(SO2), y donde los grupos de 6 o 7 miembros saturados previamente indicados, también pueden presentarse como sistemas de anillos puenteados con un puente imino, N-(alquil C1-4)-imino, metileno, alquil C1-4-metileno o di-(alquil C1-4)-metileno, y donde los grupos cíclicos previamente indicados pueden estar mono o polisustituidos en uno o varios átomos C con R20, en el caso de un grupo fenilo también adicionalmente monosustituidos con nitro, y/o uno o varios grupos NH con R21, R4 uno de los significados indicados para R17, alquenilo C3-6 o alquinilo C3-6; R5a, R5b independientemente entre sí H, alquilo C1-3, cicloalquilo C3-7, cicloalquil C3-alquilo C1-3, CF3, F o Cl, donde R5a y R5b en el significado alquilo pueden estar unidos de modo tal entre sí, que junto con el átomo C, al que están unidos R5a y R5b, se forma un grupo cicloalquilo C3-7, R7a, R7c independientemente entre sí, H, F, Cl, alquilo C1-4 o CF3, R7b, R7d independientemente entre sí H, F, alquilo C1-4, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-3 o CF3, donde R7a y R7b en el significado alquilo pueden estar unidos de modo tal entre sí, que junto con el átomo C al que están unidos R7a y R7b, se forma un grupo cicloalquilo C3-7, y/o donde R7c y R7d en el significado alquilo pueden estar unidos de modo tal entre sí, que junto con el átomo C al que están unidos R7c y R7d, se forma un grupo cicloalquilo C3-7, o donde R7b y R7d en el significado alquilo pueden estar unidos de modo tal entre sí, que junto con los dos átomos C, al que están unidos R7b t R7d, se forma un grupo cicloalquilo C3-7; R10 hidroxi, hidroxi-alquilo C1-3 o, alcoxi C1-4, (alcoxi C1-4)-alquilo C1-3, carboxi, alcoxi C1-4 carbonilo, amino, alquil C1-4-amino, di-(alquil C1-4)-amino, ciclo-alquilenimino C3-6, amino-alquilo C1-3, alquil-C1-4-amino-alquilo C1-3, di-(alquil C1-4)-amino-alquilo C1-3, ciclo-alquilenimino C3-6-alquilo C1-3, amino-alcoxi C1-3, alquil C1-4-amino-alcoxi C1-3, di-alquil C1-4)-amino-alcoxi C1-3, ciclo-alquilenimino C3-6-alcoxi C1-3, aminocarbonilo, alquil C1-4-aminocarbonilo, di-/alquil C1-4)- aminocarbonilo o ciclo-alquilenimino C3-6-carbonilo; R11 alquilo C1-3 o, alquenilo C2-6, alquinilo C2-6, R15-O, R15-O-alquilo C1-3, R15-O-CO, R15-CO-O, ciano, R16R17N, R18R19N-CO- o Cy; R13 uno de los significados indicados para R17; R14 halogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, R15-O, R15-O-CO, R15-CO, R15-CO-O, R16R17N, R18R19N-CO-, R15-O-alquilo C1-3, R15-O-CO-alquilo C1-3o , R15-O-CO-NH, R15-SO2-NH, R15-O-CO-NH-alquilo C1-3, R15-SO2-NH-alquilo C1-3, R15-CO-alquilo C1-3, R15- CO-O-alquilo C1-3, R16R17N-alquilo C1-3, R18R19N-CO-alquilo C1-3 o o Cy-alquilo C1-3-; R15 H, alquilo C1-4o, cicloalquilo C3-7, cicloalquilo C3-7-alquilo C1-3, fenilo, fenil-alquilo C1-3, piridinilo o piridinil-alquilo C1-3-, R16 H, alquilo C1-6, cicloalquilo C3-7,cicloalquilo C3-7-alquilo C1-3, cicloalquenilo C4-7, cicloalquenilo C4-7-alquilo C1-3, hidroxi-alquilo C2-3, alcoxi C1-4-alquilo C2-3, amino-alquilo C2-6, alquil C1-4-amino-alquilo C2-6, di-(alquil C1-4)-amino-alquilo C2-6o o ciclo- alquilenimino C3-6-alquilo C2-6; R17 uno de los significados indicados para R16 o fenilo, fenil-alquilo C1-3, piridinilo, Dioxolan-2-ilo, alquil-C1-4 carbonilo, hidroxicarbonil-alquilo C1-3, alcoxi C1-4-carbonilo, alcoxi C1-4-carbonil-alquilo C1-3, alquil C1-4 carbonilamino-alquilo C2-3, N-(alquil C1-4-carbonil)-N-(alquil C1-4)-amino-alquilo C2-3, alquil- C1-4 sulfonilo, alquil C1-4-sulfonil-amino-alquilo C2-3 o N-(alquil C1-4 sulfonilo)-N-(alquil C1-4)-amino-alquilo C2-3-; R18, R19 independientemente entre sí significan H o alquilo C1-6; R20 halogeno, hidroxi, ciano, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-3, hidroxi-alquilo C1-4, R22-alquilo C1-3 o uno de los significados indicados para R22; R21 alquilo C1-4o, hidroxi-alquilo C2-3, alcoxi C1-4-alquilo C2-6, alquil C1-4-amino-alquilo C2-6, di-(alquil C1-4)-amino-alquilo C2-6, ciclo-alquilenimino C3-6-alquilo C2-6, fenil-alquilo C1-3, alquil C1-4-carbonilo, alcoxi C1-4- carbonilo o alquil C1-4 sulfonilo; R22 fenil-alcoxi C1-3, ciclo-alquilenimino C3-6-alcoxi C2-4, alcoxi C1-4, alquil C1-4-tio, carboxi, alquil C1-4 carbonilo, alcoxi C1-4 carbonilo, aminocarbonilo, alquil C1-4-amino-carbonilo, di-(alquil C1-4)- aminocarbonilo, cicloalquil C3-6-amino-carbonilo, ciclo-alquilenimino C3-6-carbonilo, ciclo-alquilenimino C3-6-alquil C2-4-aminocarbonilo, fenil-amino-carbonilo, alquil C1-4-sulfonilo, alquil C1-4-sulfinilo, alquil C1-4-sulfonilamino, amino, alquil C1-4 amino, di-(alquil C1-4)amino, alquil C1-4-carbonil-amino, ciclo-alquilenimino C3-6, fenil-alquil C1-3 amino, N-(alquil C1-4)-fenil-alquil C1-3-amino, acetilamino, propionilamino, fenilcarbonilamino, fenilcarbonilmetilamino, hidroxi-alquil C1-3- aminocarbonilo, (4-morfolinil)-carbonilo, (1-pirrolidinil)-carbonilo, (1-piperidinil)-carbonilo, (hexahidro-1-azepinil)-carbonilo, (4-metil-1-piperazinil)-carbonilo, aminocarbonilamino o alquil C1-4-aminocarbonil-amino, donde en los grupos y radicales antes mencionados, especialmente en X, R1 hasta R4, R10, R11, R13 hasta R22, en cada caso uno o varios átomos C pueden estar mono o polisustituidos adicionalmente con F y/o en cada caso uno o dos átomos C independientemente entre sí, adicionalmente monosustituidos con Cl o Br y/o en cada caso uno o varios anillos fenilo independientemente entre sí pueden presentar adicionalmente uno, dos o tres sustituyentes seleccionados del grupo F, Cl, Br, I, alquilo C1-4, alcoxi C1-4, difluorometilo, trifluorometilo, hidroxi, amino, alquil C1-3-amino, di-(alquil C1-3)-amino, acetilamino, aminocarbonThis refers to beta-ketoamide compounds of the general formula (1) in which: R1, R2 independently of each other means H, a mono- or C3-7 cycloalkyl group mono or possibly polysubstituted with the radical R11, where a group - CH2- can be substituted in position 3 or 4 of a cycloalkyl group of 5, 6 or 7 members with -O-, -S- or -NR13, or a phenyl or pyridinyl radical, possibly mono or polysubstituted with the radical R20 and / or with nitro, or R1 and R2 form a C2-8 alkylene bridge, in which one or two groups -CH2- independently of each other may be substituted with -CH = N- or -CH = CH- and / or one or two groups -CH2- independently of each other can be substituted with -O, -S, -SO, - (SO2), -CO, -C (= CH2) - or - NR13- so that the heteroatoms are not attached directly to each other, and that a group -CO- is not directly linked to the group R1R2N, where the alkylene bridge defined above one or more H atoms may be substituted with R14, and where the previously defined alkylene bridge can be substituted with one or two identical or different Cy carbo or heterocyclic groups such that the union between the alkylene bridge and the Cy group is carried out through a single or double bond, through of a joint C atom by forming a spirocyclic ring system, through two C and / or N joint atoms, adjacent by forming a condensed bicyclic ring system or through three or more C and / atoms or N by the formation of a bridged ring system, R 3 H, C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C 1-4 alkyl- or phenyl-C 1-3 alkyl; X a C1-8 alkylene bridge, in which a group -CH2, which is not directly linked with the group R1R2N, can be substituted with -CH = CH- or -C ::: C- and / or one or two groups - Non-adjacent CH2-, which are not directly linked to the group R1R2N, can be independently substituted with each other with -O, -S, - (SO), - (SO2), - CO- or -NR4- so that in each case two atoms O, S or N or an atom O with an atom S are not directly linked to each other, where the bridge X can be linked with R1 including the atom of N linked with R1 and X forming a heterocyclic group, where the X bridge can additionally also be linked to R2 including the N atom attached to R2 and X forming a heterocyclic group, and where two C atoms or a C atom and an N atom of the alkylene bridge can be linked together by a C1-4 alkylene bridge additional and where a C atom not directly linked with a heteroatom may be substituted with R10 and / or one or two C atoms substituted in each case with u no or two identical or different substituents selected from C 1-6 alkyl, 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C 1-3 alkyl, C 4-7 cycloalkenyl and C 4-7 cycloalkenyl -C1-3 alkyl, where two alkyl and / or alkenyl substituents can be linked together forming a carbocyclic ring system, and Z a simple bond or -CR7aR7b-CR7cR7d, and one of the meanings indicated for Cy, where R1 may be bound with Y including the group X and the atom N linked with R1 and X forming a heterocyclic group fused to Y, and / or where X can be linked to Y forming a carbo or heterocyclic group fused to Y, and A one of the meanings indicated for Cy, B one of the meanings indicated for Cy, b the value 0 or 1; Cy a carbo or heterocyclic group selected from one of the following meanings: a saturated carbocyclic group of 3 to 7 members, an unsaturated carbocyclic group of 4 to 7 members, a phenyl group, a saturated heterocyclic group of 4 to 7 members or not 5-member saturated with an N, O or S atom as a heteroatom, a saturated or unsaturated 5 to 7 member heterocyclic group with two or several N atoms or with one or two N atoms and an O or S atom as heteroatoms, a 5 or 6-membered heterocyclic aromatic group with one or several same or different heteroatoms selected from N, O and / or S, where groups of 4, 5, 6- or 7 members may be joined in form through two C atoms adjacent sets fused with a phenyl or pyridine ring, and where in the groups of 5, 6- or 7 members mentioned above, one or two non-adjacent groups -CH2- independently of each other may be substituted with a group -CO, -C ( = CH2), - (SO) - or - (SO2), and where the group s of 6 or 7 saturated members previously indicated, can also be presented as bridged ring systems with an imino, N- (C1-4 alkyl) -imino, methylene, C1-4 alkyl-methylene or di- (C1-4 alkyl) bridge ) -methylene, and where the cyclic groups indicated above may be mono or polysubstituted in one or more C atoms with R20, in the case of a phenyl group also additionally monosubstituted with nitro, and / or one or more NH groups with R21, R4 one of the meanings indicated for R17, C3-6 alkenyl or C3-6 alkynyl; R5a, R5b independently of each other H, C1-3 alkyl, C3-7 cycloalkyl, C3 cycloalkyl-C1-3 alkyl, CF3, F or Cl, where R5a and R5b in the meaning alkyl can be linked in such a way that together with the atom C, to which R5a and R5b are attached, a C3-7 cycloalkyl group, R7a, R7c is formed independently of each other, H, F, Cl, C1-4 alkyl or CF3, R7b, R7d independently of each other H , F, C1-4 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-3 alkyl or CF3, where R7a and R7b in the meaning alkyl can be linked in such a way that together with the C atom to which R7a and R7b are attached, a C3-7 cycloalkyl group is formed, and / or where R7c and R7d in the alkyl meaning can be linked in such a way that, together with the atom C to which R7c and R7d are attached, it forms a C3-7 cycloalkyl group, or where R7b and R7d in the alkyl meaning can be linked in such a way that, together with the two C atoms, to which R7b and R7d are attached, f forms a C3-7 cycloalkyl group; R10 hydroxy, hydroxy-C1-3alkyl or, C1-4alkoxy, (C1-4alkoxy) -C1-3alkyl, carboxy, C1-4alkoxycarbonyl, amino, C1-4alkyl-alkyl, di- (C1-alkyl -4) -amino, C3-6 cycloalkylimino, C1-3alkyl-alkyl, C1-4alkyl-C1-3alkyl, di- (C1-4alkyl) -amino-C1-3alkyl, cycle -C3-6 alkyleneimino-C1-3alkyl, C1-3 amino-alkoxy, C1-4alkyl-C1-3alkoxy, di -C1-4alkyl) -amino-C1-3alkoxy, C3- cyclo-alkyleneimino 6-C 1-3 alkoxy, aminocarbonyl, C 1-4 alkylcarbonyl, di- / C 1-4 alkyl) aminocarbonyl or C 3-6 cycloalkylimino; R11 C1-3 alkyl or, C2-6 alkenyl, C2-6 alkynyl, R15-O, R15-O-C1-3 alkyl, R15-O-CO, R15-CO-O, cyano, R16R17N, R18R19N-CO- or Cy; R13 one of the meanings indicated for R17; R14 halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, R15-O, R15-O-CO, R15-CO, R15-CO-O, R16R17N, R18R19N-CO-, R15-O-alkyl C1-3, R15-O-CO-C1-3 alkyl, R15-O-CO-NH, R15-SO2-NH, R15-O-CO-NH-C1-3 alkyl, R15-SO2-NH-C1 alkyl -3, R15-CO-C1-3 alkyl, R15- CO-O-C1-3 alkyl, R16R17N-C1-3 alkyl, R18R19N-CO-C1-3 alkyl or Cy-C1-3 alkyl; R 15 H, C 1-4 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C 1-3 alkyl, phenyl, phenyl-C 1-3 alkyl, pyridinyl or pyridinyl-C 1-3 alkyl, R 16 H, C 1-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-3 alkyl, C4-7 cycloalkenyl, C4-7 cycloalkenyl-C3-3 alkyl, hydroxy-C2-3 alkyl, C1-4 alkoxy-C2-3 alkyl, amino-alkyl C2-6, C1-4 alkyl-C2-6 alkyl, di- (C1-4 alkyl) -amino-C2-6o alkyl or C3-6 cycloalkylimino-C2-6 alkyl; R17 one of the meanings indicated for R16 or phenyl, phenyl-C 1-3 alkyl, pyridinyl, Dioxolan-2-yl, C 1-4 alkylcarbonyl, hydroxycarbonyl-C 1-3 alkyl, C 1-4 alkoxycarbonyl, C 1- alkoxy 4-carbonyl-C1-3 alkyl, C1-4 alkylcarbonylamino-C2-3 alkyl, N- (C1-4 alkyl-carbonyl) -N- (C1-4 alkyl) -amino-C2-3 alkyl, C1-alkyl -4 sulfonyl, C1-4 alkyl-sulfonyl-amino-C2-3 alkyl or N- (C1-4 alkyl sulfonyl) -N- (C1-4 alkyl) -amino-C2-3- alkyl; R18, R19 independently of each other means H or C1-6 alkyl; R20 halogen, hydroxy, cyano, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-3 alkyl, hydroxy-C1-4 alkyl, R22-C1-3 alkyl or one of the meanings indicated for R22; R21 C1-4 alkyl, hydroxy C2-3 alkyl, C1-4 alkoxy-C2-6 alkyl, C1-4 alkyl-C2-6 alkyl, di- (C1-4 alkyl) -amino-C2-6 alkyl , C3-6 cyclo-alkyleneimino-C2-6 alkyl, phenyl-C 1-3 alkyl, C 1-4 alkylcarbonyl, C 1-4 alkoxycarbonyl or C 1-4 alkyl sulfonyl; R22 phenyl-C 1-3 alkoxy, C 3-6 cycloalkylimino-C 2-4 alkoxy, C 1-4 alkoxy, C 1-4 alkylthio, carboxy, C 1-4 alkylcarbonyl, C 1-4 alkoxycarbonyl, aminocarbonyl, C 1-4 alkyl -4-amino-carbonyl, di- (C1-4alkyl) -aminocarbonyl, C3-6-cycloalkylcarbonyl, C3-6 -alkyl cycloalkylimino, C3-6 -C2-4 -alkyl-cycloalkyliminocarbonyl, phenyl-amino-carbonyl, C1-4 alkyl sulfonyl, C1-4 alkyl sulfinyl, C1-4 alkyl sulfonylamino, amino, C1-4 alkyl amino, di- (C1-4 alkyl) amino, C1-4 alkyl carbonyl amino, C3-6 cycloalkylimino, phenyl-C1-3alkyl amino, N- (C1-4alkyl) -phenyl-C1-3alkyl, acetylamino, propionylamino, phenylcarbonylamino, phenylcarbonylmethylamino, hydroxy-C1-alkyl 3- aminocarbonyl, (4-morpholinyl) -carbonyl, (1-pyrrolidinyl) -carbonyl, (1-piperidinyl) -carbonyl, (hexahydro-1-azepinyl) -carbonyl, (4-methyl-1-piperazinyl) -carbonyl, aminocarbonylamino or C1-4-alkylcarbonyl-amino alkyl, where in the aforementioned groups and radicals, especially in X, R 1 to R4, R10, R11, R13 to R22, in each case one or more C atoms may be mono or additionally polysubstituted with F and / or in each case one or two C atoms independently of one another, additionally monosubstituted with Cl or Br and / or in each case one or several phenyl rings independently of one another may additionally have one, two or three substituents selected from the group F, Cl, Br, I, C1-4 alkyl, C1-4 alkoxy, difluoromethyl, trifluoromethyl, hydroxy, amino , C1-3-alkyl, di- (C1-3-alkyl) -amino, acetylamino, aminocarbon

ARP050100829A 2004-03-06 2005-03-04 NEW BETA-CETOAMIDE COMPOUNDS WITH ANCHANGISTIC EFFECT OF MCH AND MEDICINES CONTAINING THESE COMPOUNDS AR048254A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004010893A DE102004010893A1 (en) 2004-03-06 2004-03-06 New β-ketoamide compounds having MCH antagonist activity and medicaments containing these compounds

Publications (1)

Publication Number Publication Date
AR048254A1 true AR048254A1 (en) 2006-04-12

Family

ID=34877445

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100829A AR048254A1 (en) 2004-03-06 2005-03-04 NEW BETA-CETOAMIDE COMPOUNDS WITH ANCHANGISTIC EFFECT OF MCH AND MEDICINES CONTAINING THESE COMPOUNDS

Country Status (9)

Country Link
EP (1) EP1730130A1 (en)
JP (1) JP2007527424A (en)
AR (1) AR048254A1 (en)
CA (1) CA2552907A1 (en)
DE (1) DE102004010893A1 (en)
PE (1) PE20060001A1 (en)
TW (1) TW200540142A (en)
UY (1) UY28790A1 (en)
WO (1) WO2005085221A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
US7553836B2 (en) * 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
EP2069327B1 (en) 2006-08-25 2013-10-16 Boehringer Ingelheim International GmbH New pyridone derivatives with mch antagonistic activity and medicaments comprising these compounds
CL2007003580A1 (en) 2006-12-11 2009-03-27 Boehringer Ingelheim Int Pyridazine derived compounds, mch antagonists; pharmaceutical composition comprising said compound; preparation procedure; and use of the compound in the treatment of metabolic disorders and / or eating disorders such as obesity, bulimia, anorexia, hyperphagia, diabetes.
JP2010526038A (en) * 2007-05-03 2010-07-29 ノイロサーチ アクティーゼルスカブ Β-keto-amide derivatives useful as ion channel modulators
US20130143869A1 (en) * 2010-07-16 2013-06-06 Merz Pharma Gmbh & Co. Kgaa Use of a cationic amphiphilic drug for the preparation of a formulation for the reduction of subcutaneous adipose tissue

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2589004A (en) * 1948-11-04 1952-03-11 Eastman Kodak Co Process for producing couplers from bi-functional amines
GB784422A (en) * 1955-01-29 1957-10-09 Ilford Ltd Improvements in or relating to colour photography
US3341532A (en) * 1967-02-15 1967-09-12 American Cyanamid Co Substituted 7-acetylamino cephalosporanic acids
EP1218336A2 (en) * 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
CZ20021653A3 (en) * 1999-10-15 2002-08-14 F. Hoffmann-La Roche Ag Novel benzodiazepine derivatives
US6930185B2 (en) * 2000-04-28 2005-08-16 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
IL153645A0 (en) * 2000-07-31 2003-07-06 Smithkline Beecham Plc Carboxamide compounds and their use as antagonists of a human 11cby receptor
GB0124627D0 (en) * 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
TW200540142A (en) 2005-12-16
EP1730130A1 (en) 2006-12-13
CA2552907A1 (en) 2005-09-15
DE102004010893A1 (en) 2005-09-22
WO2005085221A1 (en) 2005-09-15
UY28790A1 (en) 2005-11-30
PE20060001A1 (en) 2006-02-03
JP2007527424A (en) 2007-09-27

Similar Documents

Publication Publication Date Title
AR041734A1 (en) ALKIN COMPOUNDS WITH ANTAGONIC EFFECT OF HCM AND MEDICINES CONTAINING THESE COMPOUNDS
AR041735A1 (en) AMIDA COMPOUNDS WITH MCH ANTAGONIST ACTION AND MEDICINES CONTAINING THESE COMPOUNDS
AR043046A1 (en) AMBO COMPOUNDS OF CARBOXILIC ACID WITH ANTAGONIC EFFECT OF HCM, MEDICATIONS CONTAINING THESE COMPOUNDS AND PROCEDURES FOR THEIR PREPARATION
AR048254A1 (en) NEW BETA-CETOAMIDE COMPOUNDS WITH ANCHANGISTIC EFFECT OF MCH AND MEDICINES CONTAINING THESE COMPOUNDS
AR057982A1 (en) ARILO [HETERO) COMPOUNDS WITH MCH ANTAGONIST ACTIVITY AND PHARMACEUTICAL COMPOSITION THAT INCLUDES THESE COMPOUNDS
AR048691A1 (en) COMPOUNDS WITH ALQUINO STRUCTURE WITH MCH ANTAGONIST ACTION AND MEDICINES CONTAINING THESE COMPOUNDS
AR062510A1 (en) PIRIDONA DERIVATIVES WITH MCH ANTAGONIST ACTIVITY AND MEDICINES THAT UNDERSTAND THESE COMPOUNDS
AR064293A1 (en) PIRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES TO PREVENT AND / OR TREAT DISEASES ASSOCIATED WITH MELANINE CONCENTRATING HORMONE: MCH.
AR063240A1 (en) DERIVATIVES OF N-ARIL PIRAZOL, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES FOR THE TREATMENT OF TYPE2 DIABETES, AND RELATED ILLNESSES.
AR091790A1 (en) DERIVATIVES OF ISOQUINOLIN-1-ONA AND ITS USES
AR092108A1 (en) PIRIDAZINE 1.4 DISSTITUTED, ANALOGS OF THE SAME AND METHODS TO TREAT DISEASES RELATED TO SMN DEFICIENCY
AR117139A1 (en) DERIVATIVES OF PYRIDOOXAZINONE AS INHIBITORS OF MONOACILGLICEROL LIGASE (MAGL)
AR079553A1 (en) DERIVATIVES OF DIAZA-ESPIRO- [5,5] -UNDECANOS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME IN THE TREATMENT OF CNS DISORDERS, SUCH AS DISORDERS OF THE SOUND AND DEPENDENCY, AMONG OTHERS.
AR087760A1 (en) HETEROCICLILAMINAS AS PI3K INHIBITORS
AR110139A1 (en) MONO AND SPIROCYCLES COMPOUNDS CONTAINING CYCLLOBUTAN AND AZETIDINE AS INHIBITORS OF INTEGRINE AV
AR066669A1 (en) IMIDAZOLONA DERIVATIVES AS INHIBITORS OF BENCIMIDAZOLONA QUIMASA. PHARMACEUTICAL COMPOSITIONS.
AR077434A1 (en) COMPOUNDS FOR REDUCTION OF BETA PRODUCTION - AMILOID
AR051294A1 (en) HETEROCICLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF ESTEAROIL-COA DESATURASA
AR063912A1 (en) DERIVATIVES OF 1,2,4 OXADIAZOL. PHARMACEUTICAL COMPOSITIONS.
AR073480A1 (en) BENZAMIDAS, ITS PREPARATION AND ITS USE AS MEDICATIONS
AR090548A1 (en) BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS
AR052943A1 (en) DERIVATIVES OF 2- (4-OXO-4H-QUINAZOLIN-3-IL) ACETAMIDE
AR074002A1 (en) PIRAZOLO AND IMIDAZOPIRIDINILPIRIMIDINAMINAS AS INHIBITORS OF KINASA TYROSINE (IGR-IR)
AR071300A1 (en) COMPOUNDS; PHARMACEUTICAL COMPOSITIONS BASED ON THE COMPOUND AND USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
AR060535A1 (en) PIRIDO-PIRIDAZINONAS AND FTALAZINONAS AS DUAL ANTAGONISTS OF THE H1 AND H3 RECEPTORS OF HISTAMINE

Legal Events

Date Code Title Description
FB Suspension of granting procedure